NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?

Abstract

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases are both highly prevalent conditions around the world, and emerging data have shown an association between them. This review found several longitudinal and cross-sectional studies showing that NAFLD was associated with coronary artery disease, cardiac remodeling, aortic valve remodeling, mitral annulus valve calcifications, diabetic cardiomyopathy, diastolic cardiac dysfunction, arrhythmias, and stroke. Although the specific underlying mechanisms are not clear, many hypotheses have been suggested, including that metabolic syndrome might act as an upstream metabolic defect, leading to end-organ manifestations in both the heart and liver. Management of NAFLD includes weight loss through lifestyle interventions or bariatric surgery, and pharmacological interventions, often targeting comorbidities. Although there are no Food and Drug Administration–approved nonalcoholic steatohepatitis-specific therapies, several drug candidates have demonstrated effect in the improvement in fibrosis or nonalcoholic steatohepatitis resolution. Further studies are needed to assess the effect of those interventions on cardiovascular outcomes, the major cause of mortality in patients with NAFLD. In conclusion, a more comprehensive, multidisciplinary approach to diagnosis and management of patients with NAFLD and cardiovascular diseases is needed to optimize clinical outcomes.

Keywords

nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - cardiovascular diseases - coronary artery disease - heart failure

Publikationsverlauf

Artikel online veröffentlicht:
14. Oktober 2022

• References

• 1 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
• 2 Lazarus JV, Mark HE, Anstee QM. et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19 (01) 60-78
• 3 Lazarus JV, Mark HE, Villota-Rivas M. et al; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?. J Hepatol 2022; 76 (04) 771-780
• 4 Lazarus JV, Mark HE, Colombo M. et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther 2022; 55 (02) 234-243
• 5 Duell PB, Welty FK, Miller M. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 0(0):10.1161/ATV.0000000000000153.
• 6 Lazarus JV, Anstee QM, Hagström H. et al. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021; 18 (10) 717-729
• 7 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (01) 328-357
• 8 Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389-97.e10
• 9 Sanyal AJ, Van Natta ML, Clark J. et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385 (17) 1559-1569
• 10 Sanyal AJ, Campbell-Sargent C, Mirshahi F. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120 (05) 1183-1192
• 11 Marchesini G, Brizi M, Morselli-Labate AM. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (05) 450-455
• 12 Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 2020; 4 (04) 478-492
• 13 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51 (03) 433-445
• 14 Younossi ZM, Loomba R, Anstee QM. et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68 (01) 349-360
• 15 Neuschwander-Tetri BA, Clark JM, Bass NM. et al; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52 (03) 913-924
• 16 Saadeh S, Younossi ZM, Remer EM. et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123 (03) 745-750
• 17 Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken) 2018; 11 (04) 98-104
• 18 Sumida Y, Yoneda M, Hyogo H. et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2
• 19 Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (04) 846-854
• 20 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021; 398 (10308): 1359-1376
• 21 Ginès P, Castera L, Lammert F. et al; LiverScreen Consortium Investigators. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 2022; 75 (01) 219-228
• 22 Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis 2016; 48 (12) 1410-1417
• 23 Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016; 6: 33386
• 24 Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH. Fatty liver index and development of cardiovascular disease: findings from the UK biobank. Dig Dis Sci 2021; 66 (06) 2092-2100
• 25 Lauridsen BK, Stender S, Kristensen TS. et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J 2018; 39 (05) 385-393
• 26 Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology . n/a(n/a).
• 27 Söderberg C, Stål P, Askling J. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (02) 595-602
• 28 Wu W, Xiang J, Chen X. Association between diabetes mellitus and all-cause and cardiovascular mortality among individuals with ultrasound-defined non-alcoholic fatty liver disease. Front Endocrinol (Lausanne) 2021; 12: 773342
• 29 Mantovani A, Csermely A, Petracca G. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6 (11) 903-913
• 30 Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006; 113 (24) 2851-2860
• 31 Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest 2012; 35 (02) 215-218
• 32 Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity (Silver Spring) 2017; 25 (08) 1313-1316
• 33 Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011; 124 (02) 103-110
• 34 Di Minno MND, Di Minno A, Ambrosino P, Songia P, Tremoli E, Poggio P. Aortic valve sclerosis as a marker of atherosclerosis: novel insights from hepatic steatosis. Int J Cardiol 2016; 217: 1-6
• 35 Mantovani A, Pernigo M, Bergamini C. et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 2015; 64 (08) 879-887
• 36 Salah HM, Pandey A, Van Spall HGC, Michos ED, McGarrah RW, Fudim M. Meta-analysis of nonalcoholic fatty liver disease and incident heart failure. Am J Cardiol 2022; 171: 180-181
• 37 Alon L, Corica B, Raparelli V. et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2022; 29 (06) 938-946
• 38 Bozkurt B, Hershberger RE, Butler J. et al. 2021 ACC/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). Circ Cardiovasc Qual Outcomes 2021; 14 (04) e000102
• 39 Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13 (01) 9-19
• 40 Tourki B, Halade GV. Heart failure syndrome with preserved ejection fraction is a metabolic cluster of non-resolving inflammation in obesity. Front Cardiovasc Med 2021; 8: 695952
• 41 Plitt GD, Spring JT, Moulton MJ, Agrawal DK. Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. Expert Rev Cardiovasc Ther 2018; 16 (08) 579-589
• 42 Wijarnpreecha K, Lou S, Panjawatanan P. et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis 2018; 50 (11) 1166-1175
• 43 Chung GE, Lee JH, Lee H. et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis 2018; 272: 137-144
• 44 Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep 2020; 10 (01) 12440
• 45 Salah HM, Pandey A, Soloveva A. et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. JACC Basic Transl Sci 2021; 6 (11) 918-932
• 46 Fudim M, Sobotka PA, Dunlap ME. Extracardiac abnormalities of preload reserve: mechanisms underlying exercise limitation in heart failure with preserved ejection fraction, autonomic dysfunction, and liver disease. Circ Heart Fail 2021; 14 (01) e007308
• 47 Reddy P, Lent-Schochet D, Ramakrishnan N, McLaughlin M, Jialal I. Metabolic syndrome is an inflammatory disorder: a conspiracy between adipose tissue and phagocytes. Clin Chim Acta 2019; 496: 35-44
• 48 Rao VN, Zhao D, Allison MA. et al. Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC Heart Fail 2018; 6 (12) 999-1007
• 49 Valbusa F, Bonapace S, Agnoletti D. et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One 2017; 12 (03) e0173398
• 50 Yoshihisa A, Sato Y, Yokokawa T. et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018; 5 (02) 262-270
• 51 Peters AE, Pandey A, Ayers C. et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Fail 2021; 8 (02) 842-848
• 52 Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy. Circ Res 2018; 122 (04) 624-638
• 53 Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail 2014; 20 (05) 304-309
• 54 Mantovani A, Pernigo M, Bergamini C. et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One 2015; 10 (08) e0135329
• 55 Lee H, Kim G, Choi YJ. et al. Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus. Diabetes Metab J 2020; 44 (02) 267-276
• 56 Fudim M, Zhong L, Patel KV. et al. Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries. J Am Heart Assoc 2021; 10 (22) e021654
• 57 So-Armah KA, Lim JK, Lo Re III V. et al; VACS Project Team. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Prog Cardiovasc Dis 2020; 63 (02) 184-191
• 58 VanWagner LB, Wilcox JE, Ning H. et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc 2020; 9 (04) e014279
• 59 Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol 2016; 221: 275-279
• 60 Mantovani A, Dauriz M, Sandri D. et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int 2019; 39 (04) 758-769
• 61 Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res 2021; 49 (09) 3000605211047074
• 62 Wang M, Zhou BG, Zhang Y. et al. Association between non-alcoholic fatty liver disease and risk of stroke: a systematic review and meta-analysis. Front Cardiovasc Med 2022; 9: 812030
• 63 Promrat K, Kleiner DE, Niemeier HM. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (01) 121-129
• 64 Laursen TL, Hagemann CA, Wei C. et al. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol 2019; 11 (02) 138-149
• 65 Moretto M, Kupski C, Da Silva VD, Padoin AV, Mottin CC. Effect of Bariatric Surgery on Liver Fibrosis. Obesity Surgery 2012; 22 (07) 1044-1049 . doi: http://dx.doi.org.ezproxy.med.nyu.edu/10.1007/s11695-011-0559-y
• 66 Tai C ming, Huang C kun, Hwang J chung. et al. Improvement of Nonalcoholic Fatty Liver Disease After Bariatric Surgery in Morbidly Obese Chinese Patients. Obesity Surgery 2012; 22 (07) 1016-1021 . doi: http://dx.doi.org.ezproxy.med.nyu.edu/10.1007/s11695-011-0579-7
• 67 Schneck AS, Anty R, Patouraux S. et al. Roux-En Y gastric bypass results in long-term remission of hepatocyte apoptosis and hepatic histological features of non-alcoholic steatohepatitis. Front Physiol 2016; 7: 344
• 68 Lassailly G, Caiazzo R, Buob D. et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149 (02) 379-388 , quiz e15–e16
• 69 Caiazzo R, Lassailly G, Leteurtre E. et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014; 260 (05) 893-898 , discussion 898–899
• 70 Vargas V, Allende H, Lecube A. et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol 2012; 4 (12) 382-388
• 71 Praveen Raj P, Gomes RM, Kumar S. et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis 2015; 11 (06) 1315-1322
• 72 Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther 2021; 15: 3997-4009
• 73 Majzoub AM, Nayfeh T, Barnard A. et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021; 54 (07) 880-889
• 74 Neuschwander-Tetri BA, Loomba R, Sanyal AJ. et al; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385 (9972): 956-965
• 75 Younossi ZM, Ratziu V, Loomba R. et al; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019; 394 (10215): 2184-2196
• 76 Cusi K, Orsak B, Bril F. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165 (05) 305-315
• 77 Aithal GP, Thomas JA, Kaye PV. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135 (04) 1176-1184
• 78 Belfort R, Harrison SA, Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355 (22) 2297-2307
• 79 Sanyal AJ, Chalasani N, Kowdley KV. et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
• 80 Bril F, Biernacki DM, Kalavalapalli S. et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2019; 42 (08) 1481-1488
• 81 Newsome PN, Buchholtz K, Cusi K. et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384 (12) 1113-1124
• 82 Armstrong MJ, Gaunt P, Aithal GP. et al; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387 (10019): 679-690
• 83 Francque SM, Bedossa P, Ratziu V. et al; NATIVE Study Group. A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH. N Engl J Med 2021; 385 (17) 1547-1558
• 84 Nguyen TD, Shingu Y, Amorim PA, Schenkl C, Schwarzer M, Doenst T. GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction. J Cardiovasc Transl Res 2018; 11 (03) 259-267